Founded in 2019, Altay Therapeutics develops small molecule drugs for a wide range of diseases, with a focus on chronic liver diseases like liver fibrosis and liver cancer. The company’s small molecules have potent inhibitor activity against disease-causing transcription factors by disrupting their association with DNA, and according to the company have shown exceptional results […]

View post to subscribe to site newsletter.

Egle Therapeutics is a spin-out of Institut Curie in France, developing immunotherapies targeting suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The key element of Egle’s core approach is the leveraging of its translational-based target discovery engine to unveil novel therapeutic Treg targets and vectorize computationally designed resurfaced cytokines acting as antagonists or […]

View post to subscribe to site newsletter.

Founded in 2020, US-based Known Medicine is aiming to help oncologists select the best treatment for cancer patients by providing new insights into how patients’ cells will respond to different treatments. The company is an extension of Co-Founder Andrea Mazzocchi’s research at Wake Forest University, where she recently completed a Ph.D. in biomedical engineering. The […]

View post to subscribe to site newsletter.